Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 2,452 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 2,452 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total value of $234,680.92. Following the completion of the sale, the chief executive officer owned 923,128 shares of the company’s stock, valued at $88,352,580.88. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lawrence Otto Klein also recently made the following trade(s):

• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $92.20 on Wednesday. The stock has a market capitalization of $6.10 billion, a PE ratio of -45.42 and a beta of -0.34. The business’s fifty day moving average price is $95.87 and its 200 day moving average price is $72.78. Oruka Therapeutics, Inc. has a 12-month low of $14.66 and a 12-month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Analysts remain broadly optimistic about Oruka’s pipeline. Ten analysts rate the stock a Buy, compared with one Sell rating, and the consensus price target is $133, well above the recent trading range. BTIG, Wedbush, Mizuho and HC Wainwright have maintained favorable ratings or price targets ranging from $120 to $165. Oruka analyst ratings and price targets
• Positive Sentiment: The EVERLAST-A 28-plus-week data for ORKA-001 in psoriasis is being highlighted as a key upcoming catalyst. Positive durability or efficacy results could strengthen the investment case for Oruka’s long-acting antibody platform. EVERLAST-A data catalyst article
• Neutral Sentiment: Recent insider sales were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. CEO Lawrence Klein sold 2,452 shares, SVP Arjun Agarwal sold 10,019 shares across two transactions, and Joana Goncalves sold 7,947 shares. Because the transactions were tax-related and planned in advance, they are less informative than discretionary sales, although they may still attract investor attention. Oruka insider sales report
• Negative Sentiment: Oruka remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.55 per share exceeded the expected $0.51 loss, and analysts expect a full-year loss of approximately $2.42 per share. The stock is also trading below its 50-day moving average, underscoring sensitivity to clinical updates and financing concerns.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. UBS Group upped their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Mizuho set a $120.00 price target on Oruka Therapeutics in a research report on Thursday, September 3rd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Oruka Therapeutics during the 2nd quarter valued at $474,916,000. Remedium Capital Partners LLC increased its position in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after purchasing an additional 13,247 shares during the period. Perceptive Advisors LLC raised its stake in shares of Oruka Therapeutics by 16.4% in the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after buying an additional 208,480 shares in the last quarter. Jupiter Topco LLC bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $130,968,000. Finally, Avidity Partners Management LP lifted its holdings in shares of Oruka Therapeutics by 15.1% in the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after buying an additional 100,000 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.